It has been 15 years since the advent of the genome-wide association study (GWAS) era.
Here, we review how this experimental design has realized its promise by facilitating an …

Mendelian randomization (MR) is a term that applies to the use of genetic variation to
address causal questions about how modifiable exposures influence different outcomes …

Abstract The Pharma Proteomics Project is a precompetitive biopharmaceutical consortium
characterizing the plasma proteomic profiles of 54,219 UK Biobank participants. Here we …

Mendelian randomisation (MR) studies allow a better understanding of the causal effects of
modifiable exposures on health outcomes, but the published evidence is often hampered by …

Mendelian randomization (MR) is a method of studying the causal effects of modifiable
exposures (ie, potential risk factors) on health, social, and economic outcomes using genetic …

Large-scale genome-wide association studies conducted over the last decade have
uncovered numerous genetic variants associated with cardiometabolic traits and risk factors …

The substantial investments in human genetics and genomics made over the past three
decades were anticipated to result in many innovative therapies. Here we investigate the …

This paper provides guidelines for performing Mendelian randomization investigations. It is
aimed at practitioners seeking to undertake analyses and write up their findings, and at …

Genome-wide association studies (GWAS) have revealed important biological insights into
complex diseases, which are broadly expected to lead to the identification of new drug …

Evidence on the validity of drug targets from randomized trials is reliable but typically
expensive and slow to obtain. In contrast, evidence from conventional observational …